NAVB - Navidea Biopharmaceuticals, Inc
0.250 +0.01 (3.31%)
After hours: 5:11PM EDT
| Previous Close | 0.248 |
| Open | 0.250 |
| Bid | 0.000 x 900 |
| Ask | 0.000 x 1400 |
| Day's Range | 0.230 - 0.255 |
| 52 Week Range | 0.130 - 0.680 |
| Volume | 229,306 |
| Avg. Volume | 466,522 |
| Market Cap | 43.993M |
| Beta | -1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.090 |
| Earnings Date | Mar 24, 2017 - Mar 27, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.25 |
- Benzinga•7 days ago
The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...
- Business Wire•8 days ago
Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today acceptance into the National Institutes of Health (“NIH”) Commercialization Accelerator Program (“CAP”) 2018-2019. Frederick Cope, PI) entitled 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (“RA”)-Driving Macrophages.
- Business Wire•8 days ago
Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today closing of a $3 million private placement. The Company entered into a definitive securities purchase agreement with an existing investor, John K. Scott, Jr., pursuant to which the Company received aggregate gross proceeds of $3 million in exchange for the issuance of 18,320,610 shares of the Company’s common stock, par value $0.001 per share. The securities to be issued to Mr. Scott will represent approximately 10% of the Company’s outstanding common stock after such issuance.
- Thomson Reuters StreetEvents•21 days ago
Edited Transcript of NAVB earnings conference call or presentation 16-Aug-18 9:00pm GMT
Q2 2018 Navidea Biopharmaceuticals Inc Earnings Call
- ACCESSWIRE•last month
Navidea Biopharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 16, 2018 at 5:00 ...
- Simply Wall St.•last month
What Does Navidea Biopharmaceuticals Inc’s (NYSEMKT:NAVB) Ownership Structure Look Like?
In this analysis, my focus will be on developing a perspective on Navidea Biopharmaceuticals Inc’s (NYSEMKT:NAVB) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...
- Business Wire•last month
Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting
As previously announced, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, will host a conference call today, August 16, 2018, at 5:00pm EDT to discuss details of the Annual Meeting for its shareholders, to be held today in Fort Lee, New Jersey under the chairmanship of Michael Rice, director of Navidea.
- Business Wire•last month
Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American
On August 14, 2018, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing standards as set forth in Sections 1003(a)(ii) and 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”). In order to maintain its listing, the Company must submit a plan of compliance by September 14, 2018 addressing how it intends to regain compliance with Section 1003(a)(ii) of the Company Guide by February 14, 2020.
- Associated Press•2 months ago
Navidea: 2Q Earnings Snapshot
The Dublin, Ohio-based company said it had a loss of 2 cents per share. The biopharmaceutical posted revenue of $542,100 in the period. Its adjusted revenue was $542,000. In the final minutes of trading ...
- Business Wire•2 months ago
Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results
Conference Call to be held Thursday, August 16th, 2018 at 5:00 pm ET following the Annual Meeting
- Business Wire•2 months ago
Navidea Management to Host Moderated Q&A Webcast to Provide Corporate Update
Webcast will also focus on Proxy Updates
- Business Wire•3 months ago
Navidea to Host Moderated Q&A Webcast with Management
Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer Session focused on Navidea’s clinical progress in Nonalcoholic Steatohepatitis with Jed Latkin, Chief Financial and Operating Officer, and Fred Cope, Ph.D., Chief Scientific Officer of Navidea, on Thursday June 21, ...
- Business Wire•4 months ago
Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention
Navidea Biopharmaceuticals (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 8th Annual LD Micro Invitational Conference in Bel-Air, CA being held June 4-6, 2018. Jed Latkin, Chief Financial and Operating Officer of Navidea, will be giving a corporate presentation focused on Navidea’s clinical programs. In additional, Michael Goldberg, M.D., Chief Executive Officer of Navidea, along with other members of management will attend the 2018 BIO International Convention in Boston, MA being held June 4-7, 2018 to participate in meetings with potential clinical and commercial partners, investors, and other parties.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of NAVB earnings conference call or presentation 9-May-18 12:30pm GMT
Q1 2018 Navidea Biopharmaceuticals Inc Earnings Call
- Associated Press•5 months ago
Navidea: 1Q Earnings Snapshot
The Dublin, Ohio-based company said it had a loss of 4 cents per share. The biopharmaceutical posted revenue of $276,400 in the period. Its adjusted revenue was $276,000. The company's shares closed at ...
- Business Wire•5 months ago
Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results
Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter of 2018.
- ACCESSWIRE•5 months ago
Navidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith
DUBLIN, OH / ACCESSWIRE / May 7, 2018 / Navidea Biopharmaceuticals (NYSE American: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic ...
- Business Wire•5 months ago
Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, May 9, 2018 at 8:30am E.T.
- Business Wire•5 months ago
Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit
Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 2nd Annual NASH Summit in Boston, MA being held April 23-25, 2018.
- Business Wire•5 months ago
Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights
Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it has signed a deal to provide Meilleur Technologies, Inc., a wholly owned subsidiary of Cerveau Technologies, Inc.
- ACCESSWIRE•6 months ago
Wired News – EMA to Review Regeneron’s Marketing Authorization Application for Cemiplimab
Stock Monitor: Navidea Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Regeneron Pharma, Inc. (NASDAQ: REGN ...
- Business Wire•6 months ago
Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial
Navidea Biopharmaceuticals , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on April 5, 2018 at 8:30am E.T.
- Business Wire•6 months ago
Navidea Biopharmaceuticals to Present at 25th Annual Future Leaders in the Biotech Industry
Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 25th Annual Future Leaders in the Biotech Industry in New York being held on March 23, 2018.
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of NAVB earnings conference call or presentation 8-Mar-18 9:30pm GMT
Q4 2017 Navidea Biopharmaceuticals Inc Earnings Call
- Associated Press•7 months ago
Navidea reports 4Q loss
The Dublin, Ohio-based company said it had a loss of 3 cents per share. The biopharmaceutical posted revenue of $395,100 in the period. Its adjusted revenue was $395,000. For the year, the company reported ...
